Open AccessClinical Study of Urinary Kallidinogenase in the Treatment of Progressive Cerebral Infarction
Author(s) -
Bin Fan,
Weidong Li
Publication year - 2013
Publication title -
advanced emergency medicine
Language(s) - English
Resource type - Journals
ISSN - 2315-456X
DOI - 10.18686/aem.v2i1.5
Subject(s) - medicine , urinary system , cerebral infarction , saline , adverse effect , fibrinogen , gastroenterology , urology , anesthesia , ischemia
Objective: To evaluate the efficacy and safety of Urinary kallidinogenase in the treatment of progressive cerebral infarction. Method: 104 cases of patients with acute cerebral infarction were randomly divided into treatment group and control group; where control group (52 cases) patients on with only basic medicine, while treatment group (52 cases), besides the basic medicine, patients will on urinary kallidinogenase 0.15 PNAU + 0.9% normal saline 100 mL intravenous injection, 1 times per day, and continuous for 14 days. The degree of neurological impairment (NIHSS) was assessed before and after treatment, and the changes of blood pressure were monitored. The liver, renal function, fibrinogen, platelet, and the adverse reactions were recorded and followed up in three month. Results : After treatment, NIHSS scores of the both groups were decreased ( p < 0.05), however, total effective rate for treatment group were better than control group ( p < 0.05). Conclusion: Urinary kallidinogenase is safe and effective in the treatment of progressive cerebral infarction.